Related Experiment Video
Updated: Apr 28, 2026

Author Spotlight: Epigenetic Modifications and Metabolic Rewiring as Targets for Cancer Therapy
Published on: October 18, 2024
Multiomic screening platform uncovers the impact of histone mutations on chromatin and cell fate
Ziyang Ye1,2, Alireza Khademi1,2, Renée L Barbosa1,2
1Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, 02139, USA.
Abstract:
Somatic missense mutations in histone genes, often referred to as 'oncohistones', have been identified in diverse types of human cancers. The functional and mechanistic impact of most oncohistones remains unknown. To address this gap, we developed CHANCLA, a modular platform for high-throughput functional screening of oncohistones using multiomic phenotypic readouts. We used CHANCLA to systematically measure the impact of 303 human oncohistones on cellular proliferation, differentiation, histone-specific post-translational modifications, and chromatin accessibility. Integrative multiomic analyses revealed discrete oncohistone molecular classes that promote proliferation, block lineage-specific differentiation, and physically remodel the chromatin landscape by altering specific histone modifications and reducing nucleosome stability. Structural mapping and computational modeling studies uncovered that functionally convergent mutations are clustered at key nucleosome interfaces, particularly H2B-H4, and that chromatin accessibility-promoting mutations are linked to mono-nucleosome destabilization. Leveraging this multiomic resource, we discovered that the H3.3-Q5H mutant histone is a bona fide human oncohistone that accelerates lung adenocarcinoma growth in vivo. Mechanistically, we found that H3.3-Q5H expression leads to suppression of promoter-associated H3K4me3 and expansion of repressive H3K27me3 domains, resulting in increased KRAS signaling and gene expression programs associated with epithelial-to-mesenchymal transition. Together, this work provides a multiomic functional atlas of cancer-associated histone mutations, identifies structural and mechanistic principles governing chromatin reprogramming by oncohistones, and establishes CHANCLA as a modular platform for systematic discovery of mechanisms and vulnerabilities associated with these genetic lesions.
Insights
Cancer-driving histone mutations, or oncohistones, were functionally screened using the CHANCLA platform. This revealed distinct oncohistone classes and identified H3.3-Q5H as a lung cancer driver.
Area of Science:
- * Molecular biology
- * Cancer genomics
- * Epigenetics
Background:
- * Somatic missense mutations in histone genes, termed 'oncohistones', are implicated in various human cancers.
- * The functional and mechanistic consequences of most oncohistones are not well understood.
- * Understanding oncohistone function is crucial for cancer research.
Purpose of the Study:
- * To develop a high-throughput screening platform (CHANCLA) for functional analysis of oncohistones.
- * To systematically assess the impact of 303 human oncohistones on cellular phenotypes and chromatin.
- * To elucidate the molecular mechanisms and structural underpinnings of oncohistone activity in cancer.
Main Methods:
- * Development and application of the CHANCLA (Cancer Histone Annotation and Characterization by Large-scale Assay) platform.
- * High-throughput functional screening of 303 human oncohistones using multiomic phenotypic readouts.
- * Integrative multiomic analyses, structural mapping, and computational modeling.
Main Results:
- * Identification of discrete oncohistone molecular classes influencing proliferation, differentiation, and chromatin accessibility.
- * Discovery that mutations cluster at nucleosome interfaces (e.g., H2B-H4) and affect nucleosome stability.
- * Validation of H3.3-Q5H as a bona fide oncohistone accelerating lung adenocarcinoma growth in vivo.
- * Elucidation of H3.3-Q5H mechanism: suppression of H3K4me3, expansion of H3K27me3, and promotion of KRAS signaling and EMT.
Conclusions:
- * CHANCLA provides a comprehensive multiomic atlas of cancer-associated histone mutations.
- * Oncohistones reprogram chromatin through specific structural interfaces and altered histone modifications.
- * H3.3-Q5H is a validated oncohistone driving lung adenocarcinoma via epigenetic alterations.
- * CHANCLA serves as a platform for discovering oncohistone mechanisms and therapeutic vulnerabilities.
More Related Videos
10:09Isolation and Cultivation of Neural Progenitors Followed by Chromatin-Immunoprecipitation of Histone 3 Lysine 79 Dimethylation Mark
Published on: January 26, 2018
08:12Global Level Quantification of Histone Post-Translational Modifications in a 3D Cell Culture Model of Hepatic Tissue
Published on: May 5, 2022
Related Concept Videos
Histone Modification
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
Histone Modification
Spreading of Chromatin Modifications
Writers
The writer...
Chromatin Modification in iPS Cells
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
Inheritance of Chromatin Structures
Histone Variants at the Centromere